Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Identifying the role of apolipoprotein A-I in prostate cancer.

Jing Wang | Ling-Fan Xu | Cheng Liu | Tao Huang | Chao-Zhao Liang | Yi-Dong Fan
Asian journal of andrology | 2021

Although localized prostate cancer (PCa) can be cured by prostatectomy and radiotherapy, the development of effective therapeutic approaches for advanced prostate cancer, including castration-resistant PCa (CRPC) and neuroendocrine PCa (NEPC), is lagging far behind. Identifying a novel prognostic and diagnostic biomarker for early diagnosis and intervention is an urgent clinical need. Here, we report that apolipoprotein A-I (ApoA-I), the major component of high-density lipoprotein (HDL), is upregulated in PCa based on both bioinformatics and experimental evidence. The fact that advanced PCa shows strong ApoA-I expression reflects its potential role in driving therapeutic resistance and disease progression by reprogramming the lipid metabolic network of tumor cells. Molecularly, ApoA-I is regulated by MYC, a frequently amplified oncogene in late-stage PCa. Altogether, our findings have revealed a novel indicator to predict prognosis and recurrence, which would benefit patients who are prone to progress to metastasis or even NEPC, which is the lethal subtype of PCa.

Pubmed ID: 33586698

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NCBI Epigenomics (tool)

RRID:SCR_006151

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 19, 2022.

View all literature mentions

cBioPortal (tool)

RRID:SCR_014555

A portal that provides visualization, analysis and download of large-scale cancer genomics data sets.

View all literature mentions

MetaboAnalyst (tool)

RRID:SCR_015539

Web server for statistical, functional and integrative analysis of metabolomics data. Web based tool suite used for metabolomic data processing, normalization, multivariate statistical analysis, and data annotation, biomarker discovery and classification.

View all literature mentions

Microsoft Excel (tool)

RRID:SCR_016137

Software application with data analysis tools and spreadsheet templates to track and visualize data. It is used to manage and process data.

View all literature mentions

HEK293T (tool)

RRID:CVCL_0063

Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

RWPE-1 (tool)

RRID:CVCL_3791

Cell line RWPE-1 is a Transformed cell line with a species of origin Homo sapiens

View all literature mentions

LNCaP (tool)

RRID:CVCL_0395

Cell line LNCaP is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

DU145 (tool)

RRID:CVCL_0105

Cell line DU145 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions